Podcast available at https://www.patreon.com/posts/19454630
If GW Pharmaceuticals’ CBD drug Epidiolex receives FDA approval at the end of this month, a DEA spokeswoman tells Leafly’s Ben Adlin that the agency would “absolutely” reschedule cannabidiol. CBD, as an extract of the cannabis plant, is considered a Schedule I substance under federal law. There is much confusion on the issue, owing to sellers of CBD products that misconstrue the legality of industrial hemp products as bestowing legality on cannabidiol extracted from hemp. DEA dismisses this claim on the grounds that cannabidiol cannot reasonably be extracted from the legal stalk and seeds of hemp. Rescheduling CBD to recognize its medical utility within Epidiolex also wouldn’t necessarily provide the legal cover these sellers seek. Legal CBD as an isolate wouldn’t cover so-called “whole plant extracts” and a Schedule II or lower designation for CBD would still involve a great deal of regulation from the FDA.